# Processing report — Sinha Gul 2024

## Source
- Title: The Comparison of the Effectiveness of Dapagliflozin and Empagliflozin in the Prevention of Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Network Meta-Analysis
- Authors: Tanya Sinha; Ushna Gul; Nawabzada Nadir Babar; Farhan Israr; Aqsa A. Butt; Sandipkumar S. Chaudhari; Hamza Maqbool; Adil Amin
- Journal: Cureus
- Published: 19 September 2024
- DOI: 10.7759/cureus.69711
- PMID: 39429324
- Source file: `cureus-0016-00000069711.pdf`
- SHA-256: `ac8db02bf4a4907856394d006878ffe111ef433691e01016fa50aa5e5390862b`

## ATOM
- LiteratureAtoms: 74
- Counts by kind: author_conclusion=3, comparator_description=1, conflict_of_interest=1, eligibility_criterion=5, funding_disclosure=1, intervention_description=2, limitation=4, method=16, other=5, outcome_definition=5, population_description=3, qualitative_result=12, quantitative_result=15, study_objective=1
- Pydantic structural validation: PASS
- JSON Schema validation: PASS
- Sufficiency validation: PASS
- Sufficiency errors: 0
- Sufficiency warnings: 0
- Duplicate atom IDs: 0

### Source consistency flags preserved
1. Results prose states seven observational studies and five RCTs, while Table 1 labels six observational studies and six RCTs. Petrie et al. 2020 appears in both Table 2 (RCT risk of bias) and Table 3 (observational quality), producing overlapping design classification.
2. Methods states funnel plots were used to assess small-study effects, while Limitations and Table 6 state publication bias could not be assessed because fewer than 10 studies contributed to each outcome.
3. Hospitalization-for-heart-failure prose reports empagliflozin versus dapagliflozin RR 1.02 (95% CI 0.84-1.24), whereas Figure 6 and Table 4 report the upper bound as 1.23.
4. Table 6 certainty labels are internally difficult to reconcile with its own domain judgments: some 'High' entries include serious inconsistency and/or imprecision, while some 'Low' entries list no serious inconsistency, indirectness, or imprecision.
5. Table 1 lists Wiviott 2019 and Zelniker 2020 as separate included entries with the same dapagliflozin/placebo arm sizes and 50.4-month follow-up; the Zelniker citation explicitly describes a DECLARE-TIMI 58 analysis, creating a source-level risk of overlapping trial populations if the two entries were pooled independently.

## SEA
- Main-text figures reconciled: 6/6
- Tables reconciled: 6/6, including the appendix GRADE table
- Separate supplement in selected source packet: no
- SEA QA: PASS
- Verdict: Do not use for practice as a standalone source; retain as a hypothesis-generating comparative synthesis and source map.

## References
- Bibliography entries extracted: 32
- Output format: Markdown
- Reference numbering preserved: 1–32

## Extraction limitations
- The source is a secondary systematic review/network meta-analysis. Atoms represent the review's methods, pooled/network results, evidence-quality statements, conclusions, and source-integrity observations; they do not convert the underlying trial or cohort findings into primary-study atoms.
- The LiteratureAtom schema has no dedicated NMA/GRADE/SUCRA structures; these were represented with existing atom kinds and tags without inventing fields.
- No separate supplementary file was present in the selected materials folder.
- No external evidence update was performed.
